天坛生物：“人纤维蛋白原”获得药物临床试验批准通知书

Core Viewpoint - TianTan Biological (600161) has received approval from the National Medical Products Administration for clinical trials of "human fibrinogen" to treat congenital fibrinogen deficiency or lack [1] Company Summary - TianTan Kunming, a subsidiary of TianTan Biological, has been granted a Clinical Trial Approval Notice for the drug "human fibrinogen" [1] - The drug is indicated for conditions such as congenital fibrinogen deficiency or lack [1]